In short
Clinical trials are investigating ZUNIBERGENE ROCPARVOVEC in adults with macular neovascularization secondary to age-related macular degeneration. These studies are designed to evaluate safety, efficacy, and how long the treatment effect lasts. The available trial data focus on a late-stage study in people with nAMD.
Key points
- ZUNIBERGENE ROCPARVOVEC is being studied in a Phase 3 clinical trial for adults with macular neovascularization secondary to age-related macular degeneration. The study is randomized, double-masked, and active-controlled, which means it compares treatments in a fair and blinded way. It looks at a single intravitreal injection of ZUNIBERGENE ROCPARVOVEC versus aflibercept given every 8 weeks. The main goal is to see whether vision outcomes at Week 52 are not worse than the active comparator. The trial also evaluates safety and how durable the treatment effect is. Planned enrollment is 480 participants.
Trial overview
The available trial data for ZUNIBERGENE ROCPARVOVEC describe one Phase 3 study in adults with macular neovascularization secondary to age-related macular degeneration, also called nAMD. The study is interventional, which means people in the trial receive a study treatment and are then followed to see what happens.
The trial is authorised and plans to include 480 participants. Its main purpose is to evaluate efficacy, safety, and durability of the study treatment in this eye disease.
Study design and comparison treatment
This study is described as randomized, double-masked, and active-controlled. Randomized means treatment groups are assigned by chance, double-masked means neither the participants nor the study team know which treatment is being given, and active-controlled means the study compares against another active treatment rather than no treatment.
The trial compares a single intravitreal injection of ZUNIBERGENE ROCPARVOVEC with aflibercept given every 8 weeks. Intravitreal means the treatment is injected into the eye.
The source data also state that the main efficacy goal is to show non-inferiority to aflibercept. Non-inferiority means the new treatment should not perform meaningfully worse than the comparison treatment by more than a set amount.
Who can participate
The trial is studying adults with nAMD. The data provided do not list the full inclusion or exclusion criteria, so the exact rules for joining the study are not available in the source material.
Because the condition is eye-related, the study is focused on people whose vision may be affected by abnormal blood vessel growth in the macula. The macula is the part of the retina needed for sharp central vision.
What the trial measures
The primary outcome is the mean change from baseline in BCVA ETDRS letter score at Week 52. BCVA means best corrected visual acuity, which is a standard way to measure vision with the best possible correction, such as glasses.
ETDRS letter score is a research eye-chart score used to measure vision changes more precisely than a simple yes-or-no vision result. Baseline means the starting point before treatment, and Week 52 means the assessment after one year.
The trial brief summary says the study also looks at safety and durability. Durability means how long the treatment effect lasts over time.
Trial status and size
The trial status is Authorised. This means the study has been approved to move forward in the source registry information.
The planned enrollment is 480 adults. A larger enrollment helps researchers compare outcomes more reliably across the study groups.